-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
.
The industry said that as more and more blockbuster innovative products are expected to enter the medical insurance catalog through negotiation, this is a great boon
for the majority of patients.
The National Health Insurance Administration previously announced the "List of Declared Drugs Approved for Formal Review for the Adjustment of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue in 2022", with a total of 343 drugs officially passing the formal review
.
Including 198 Western medicines and proprietary Chinese medicines outside the list, and 145 Western medicines and proprietary Chinese medicines in the catalog
.
In terms of pass rate, the proportion of drugs outside the list was 60%, and the proportion of drugs in the list was 91%.
.
Including 198 Western medicines and proprietary Chinese medicines outside the list, and 145 Western medicines and proprietary Chinese medicines in the catalog
.
In terms of pass rate, the proportion of drugs outside the list was 60%, and the proportion of drugs in the list was 91%.
It is worth mentioning that the blockbuster innovative products participating in the "soul bargaining" include the PD-1/CTLA-4 bispecific antibody cardunilimab injection independently developed by Akeso, the PD-1 serplulimab approved by Henlius in March 2022, the PD-L1 inhibitor Envolimab injection approved by Corning Jerry/Sidi/Simcere Pharmaceutical in November 2021, the CAR-T relmacel injection with millions of yuan per injection, and Hengrui Pharmaceutical's carrelizumab and Henri Pharmaceutical's carrelizumab injection.
BeiGene's tislelizumab, Innovent Cindilimab injection, Junshi Biologics teripulimab and other domestic PD-1 monoclonal antibody indications, in addition to a number of high-value rare disease drugs
.
BeiGene's tislelizumab, Innovent Cindilimab injection, Junshi Biologics teripulimab and other domestic PD-1 monoclonal antibody indications, in addition to a number of high-value rare disease drugs
.
Among them, Akeso's PD-1/CTLA4 bispecific antibody Cardunili participated in medical insurance negotiations
for the first time.
As an immuno-tumor dual antibody, the drug was approved in June 2022, and its marketing meets the needs of second- and third-line targeted therapy for cervical cancer, and opens a new stage
of independent commercialization of Akeso.
It is reported that the current price of the drug is 13220 yuan / 125 mg / bottle, in addition to actively preparing for this medical insurance negotiation, according to Akeso, "Akeso Bio is actively participating in various national and local medical security systems, and adopting patient rescue programs, the annual treatment cost is not higher than 198,000 yuan
.
" ”
for the first time.
As an immuno-tumor dual antibody, the drug was approved in June 2022, and its marketing meets the needs of second- and third-line targeted therapy for cervical cancer, and opens a new stage
of independent commercialization of Akeso.
It is reported that the current price of the drug is 13220 yuan / 125 mg / bottle, in addition to actively preparing for this medical insurance negotiation, according to Akeso, "Akeso Bio is actively participating in various national and local medical security systems, and adopting patient rescue programs, the annual treatment cost is not higher than 198,000 yuan
.
" ”
WuXi Therapeutics' anticancer drug CD19 CAR-T relmacel injection (Cignora) is also the first time to participate in medical insurance negotiations, and it is worth paying attention to
whether it can enter medical insurance.
It is reported that relmacel injection (Cignoda) is priced at 1.
29 million yuan per vial, and the drug has been approved for two indications, namely the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) in adult patients after two or more lines of systemic therapy and the treatment of refractory or relapsed follicular lymphoma (r/rFL)
within 24 months after two or more lines of systemic therapy.
This participation in the negotiation is the first indication.
whether it can enter medical insurance.
It is reported that relmacel injection (Cignoda) is priced at 1.
29 million yuan per vial, and the drug has been approved for two indications, namely the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) in adult patients after two or more lines of systemic therapy and the treatment of refractory or relapsed follicular lymphoma (r/rFL)
within 24 months after two or more lines of systemic therapy.
This participation in the negotiation is the first indication.
In addition, compared with previous rounds of catalog adjustment, this adjustment is appropriately tilted
towards special groups such as rare diseases and children.
According to research reports, among the drugs that passed the preliminary review, there are a total of 19 rare disease drugs, including stuximab introduced by BeiGene from EUSA Pharma, Roche's spinal muscular atrophy (SMA) oral drug rispram oral solution powder, Sanofi for the treatment of Fabry's disease injection agalose β
.
towards special groups such as rare diseases and children.
According to research reports, among the drugs that passed the preliminary review, there are a total of 19 rare disease drugs, including stuximab introduced by BeiGene from EUSA Pharma, Roche's spinal muscular atrophy (SMA) oral drug rispram oral solution powder, Sanofi for the treatment of Fabry's disease injection agalose β
.
As more and more blockbuster innovative products are expected to enter the medical insurance catalog through negotiation, this is a great boon
for the majority of patients.
Some insiders said that in the past two years, innovative drugs have been approved for clinical application, and drugs have soon been included in the medical insurance catalogue after they are listed, which also means that the entry threshold for medical insurance negotiations has been relaxed for innovative drugs, and medical insurance is willing to give innovative drugs more access opportunities and focus on unmet clinical needs
.
for the majority of patients.
Some insiders said that in the past two years, innovative drugs have been approved for clinical application, and drugs have soon been included in the medical insurance catalogue after they are listed, which also means that the entry threshold for medical insurance negotiations has been relaxed for innovative drugs, and medical insurance is willing to give innovative drugs more access opportunities and focus on unmet clinical needs
.
For price adjustment, a number of securities research reports believe that the price adjustment of innovative drugs should be relatively moderate in the overall negotiation of the medical insurance catalog, and give greater support to "promoting innovation" on the basis of 'basic protection', on this basis, large pharmaceutical companies with large innovation value, excellent clinical effects and cost advantages are expected to gain advantages in fierce negotiations and fully share the dividends
of the medical insurance fund.
According to the data, from 2018 to 2021, the average price of drugs negotiated by medical insurance will decrease by about 50%-60%.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). of the medical insurance fund.
According to the data, from 2018 to 2021, the average price of drugs negotiated by medical insurance will decrease by about 50%-60%.
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
